Cargando…

Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement

Brugada syndrome (BS) is an inherited cardiac ion channelopathy that is a rare, but treatable, cause of sudden cardiac death (SCD). There are many studies that explore the management of symptomatic BS, but few trials have been conducted regarding management of asymptomatic Brugada patients. Asymptom...

Descripción completa

Detalles Bibliográficos
Autores principales: Mankbadi, Michael, Hassan, Samira, McGee, Michelle, Jan, Bonnie, Mangal, Sibani, Altier, Jake, Harlapur, Manjunath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089703/
https://www.ncbi.nlm.nih.gov/pubmed/30116678
http://dx.doi.org/10.7759/cureus.2799
_version_ 1783347061595308032
author Mankbadi, Michael
Hassan, Samira
McGee, Michelle
Jan, Bonnie
Mangal, Sibani
Altier, Jake
Harlapur, Manjunath
author_facet Mankbadi, Michael
Hassan, Samira
McGee, Michelle
Jan, Bonnie
Mangal, Sibani
Altier, Jake
Harlapur, Manjunath
author_sort Mankbadi, Michael
collection PubMed
description Brugada syndrome (BS) is an inherited cardiac ion channelopathy that is a rare, but treatable, cause of sudden cardiac death (SCD). There are many studies that explore the management of symptomatic BS, but few trials have been conducted regarding management of asymptomatic Brugada patients. Asymptomatic BS patients are shown to be at increased risk (0.5%-1.5%) for SCD compared to the general population and account for nearly 20% of deaths from SCD in patients with structurally normal hearts. Treatment for asymptomatic BS patients is often debated with the current guidelines allowing for management decisions to be made on a case-by-case basis. Therapies include either anti-arrhythmic medications, implantable cardioverter-defibrillator (ICD) placement, or no active treatment. This review intended to assess whether ICD placement benefits asymptomatic BS patients and what criteria may be useful in selecting patients for ICD placement. Results showed that ICD placement can reduce mortality in select asymptomatic patients. There were certain risk factors that increased the likelihood that an asymptomatic patient would experience SCD and thus benefit from an ICD. These factors include an electrocardiogram(ECG) demonstrating spontaneous type 1 Brugada Syndrome and inducibility of ventricular tachyarrhythmias during electrophysiological study. Other variables including gender, family history of SCD, and the presence of SCN5A mutation were not predictive of arrhythmic events. Moreover, many patients can suffer complications from ICDs that can affect the quality of life including inappropriate shocks, device malfunction, infection, mental health problems, and difficulties with replacements. Guidelines for quantifying the risk of SCD relative to the risks associated with ICD placement are still poorly defined. These complications and risk factors should be taken into consideration in the context of a patient-centered discussion regarding ICD placement in asymptomatic patients.
format Online
Article
Text
id pubmed-6089703
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-60897032018-08-16 Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement Mankbadi, Michael Hassan, Samira McGee, Michelle Jan, Bonnie Mangal, Sibani Altier, Jake Harlapur, Manjunath Cureus Cardiology Brugada syndrome (BS) is an inherited cardiac ion channelopathy that is a rare, but treatable, cause of sudden cardiac death (SCD). There are many studies that explore the management of symptomatic BS, but few trials have been conducted regarding management of asymptomatic Brugada patients. Asymptomatic BS patients are shown to be at increased risk (0.5%-1.5%) for SCD compared to the general population and account for nearly 20% of deaths from SCD in patients with structurally normal hearts. Treatment for asymptomatic BS patients is often debated with the current guidelines allowing for management decisions to be made on a case-by-case basis. Therapies include either anti-arrhythmic medications, implantable cardioverter-defibrillator (ICD) placement, or no active treatment. This review intended to assess whether ICD placement benefits asymptomatic BS patients and what criteria may be useful in selecting patients for ICD placement. Results showed that ICD placement can reduce mortality in select asymptomatic patients. There were certain risk factors that increased the likelihood that an asymptomatic patient would experience SCD and thus benefit from an ICD. These factors include an electrocardiogram(ECG) demonstrating spontaneous type 1 Brugada Syndrome and inducibility of ventricular tachyarrhythmias during electrophysiological study. Other variables including gender, family history of SCD, and the presence of SCN5A mutation were not predictive of arrhythmic events. Moreover, many patients can suffer complications from ICDs that can affect the quality of life including inappropriate shocks, device malfunction, infection, mental health problems, and difficulties with replacements. Guidelines for quantifying the risk of SCD relative to the risks associated with ICD placement are still poorly defined. These complications and risk factors should be taken into consideration in the context of a patient-centered discussion regarding ICD placement in asymptomatic patients. Cureus 2018-06-13 /pmc/articles/PMC6089703/ /pubmed/30116678 http://dx.doi.org/10.7759/cureus.2799 Text en Copyright © 2018, Mankbadi et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Mankbadi, Michael
Hassan, Samira
McGee, Michelle
Jan, Bonnie
Mangal, Sibani
Altier, Jake
Harlapur, Manjunath
Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
title Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
title_full Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
title_fullStr Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
title_full_unstemmed Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
title_short Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
title_sort brugada syndrome: the role of risk stratification in selecting patients for implantable cardioverter-defibrillator placement
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089703/
https://www.ncbi.nlm.nih.gov/pubmed/30116678
http://dx.doi.org/10.7759/cureus.2799
work_keys_str_mv AT mankbadimichael brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement
AT hassansamira brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement
AT mcgeemichelle brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement
AT janbonnie brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement
AT mangalsibani brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement
AT altierjake brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement
AT harlapurmanjunath brugadasyndrometheroleofriskstratificationinselectingpatientsforimplantablecardioverterdefibrillatorplacement